Our mission: To protect the health of ear, throat and nose with medical frontier knowledge and technological innovation. Electric Nasal Aspirator, Breast Pump, Inverted Nipple Corrector Ningbo Jiamai Internet Technology CO., Ltd. , https://www.jmcuhyd.com
Our vision: Leader in several niche markets of Otolaryngology.
Our values: Change, Enterprising, Share
Medical Network on January 22, US researchers have developed a new blood test method that can detect eight common cancers that have not yet spread, and take a big step toward achieving universal early cancer detection.
The non-invasive test method called CancerSEEK was developed by researchers at Johns Hopkins University in the United States to detect ovarian cancer, liver cancer, and stomach cancer by detecting 16 cancer-related gene mutations and 8 proteins in blood samples. Pancreatic cancer, esophageal cancer, colorectal cancer, lung cancer and breast cancer.
In a recent issue of the journal Science, the researchers reported that they tested 1005 patients who had not yet metastatic cancer and 850 healthy controls and found that the specificity of the method was 99%, which means healthy people. The probability of being misdiagnosed is less than 1%.
Overall, the sensitivity or accuracy of the test is 70%, which can accurately detect 70% of cancer patients, of which ovarian cancer detection sensitivity is the highest, reaching 98%; while breast cancer detection sensitivity is the lowest, only 33% .
Among the 8 types of cancers that are suitable for this test, there are currently no screening methods for ovarian cancer, liver cancer, gastric cancer, pancreatic cancer and esophageal cancer, and the detection sensitivity is above 69%.
In addition, the test provides accurate information on the location of the tumor in 83% of patients, which has been difficult in the past.
The researchers estimate that the cost of such a test may be less than $500, which is comparable to or lower than the current cost of screening a single type of cancer.
Experts say the prospects for the test are good, but more research is needed. In addition, its sensitivity to some cancers is not high enough, which means that a significant proportion of early cancer patients may be missed.